ArticleScientific reports2025
Chlorophyllum molybdites-synthesized manganese oxide nanoparticles (MnO-NPs): morphology, biocompatibility, and anticancer properties against liver cancer (HepG2) cell line.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticles synthesized from natural sources are gaining prominence for their unique physicochemical properties and biocompatibility. This study investigates the potential of wild mushrooms, specifically Chlorophyllum molybdites (Lepiota morganii, green-spored parasol), for the green synthesis of manganese oxide nanoparticles. Mycosynthesized nanoparticles (NPs) were characterized via spectroscopic techniques such as XRD, UV spectroscopy, FTIR, and microscopic techniques such as SEM, and EDX, confirming their crystalline structure, spherical morphology, and a nanoscale size of 19.85 nm. FTIR analysis identified functional groups such as flavonoids, phenolics, and proteins, suggesting their role in nanoparticle stabilization and biological activity. Biocompatibility assays demonstrated minimal hemolysis (0.109 ± 0.05% at 400 µg/mL), indicating safety for biomedical use. Antileishmanial activity against Leishmania tropica (a flagellate parasite) revealed concentration-dependent inhibition, with IC50 values of 250 µg/ml and 224 µg/ml for promastigotes and amastigotes, correspondingly. Cytotoxic effects on HepG2 liver cancer cells were evaluated using MTT and crystal violet assays, showing significant dose-dependent reduction in cell viability (IC50 = 50 µg/mL) and apoptosis induction. Furthermore, comparative MTT assays confirmed enhanced efficacy of nanoparticles synthesized with Chlorophyllum molybdites. These results confirmed the multifaceted biomedical effeciacy of mycosynthesized nanoparticles, including anticancer and antiparasitic applications, while promoting sustainable nanoparticle synthesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.